Lisa Ricciardi, Cognition CEO (UDG Healthcare)

NIH — and some fa­mil­iar play­ers — back a PhII Alzheimer’s gam­ble in an­oth­er stab at the amy­loid hy­poth­e­sis

Cog­ni­tion Ther­a­peu­tics has a $76 mil­lion grant from the NIH to try out its ap­proach to guard­ing against the synap­tic dam­age be­hind the cas­cade of events that brings on Alzheimer’s. And they’re em­ploy­ing some well-known play­ers in the field for the work.

The New York-based biotech re­port­ed Mon­day morn­ing that the NIH has com­mit­ted to back­ing their Phase II tri­al for CT1812 in 540 ear­ly-stage pa­tients over the next 3 years. Cog­ni­tion says they’ll be car­ry­ing out the study along with the NIH-fund­ed Alzheimer’s Clin­i­cal Tri­al Con­sor­tium.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.